Clinical trial
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and…
NCT00297570 · Sheba Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00297570 |
|---|---|
| Title | Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy |
| Lead sponsor | Sheba Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Philadelphia-Positive |
| Intervention type | Drug |
| Interventions | Pegylated Interferon and Imatinib |
| Enrollment | 90 |
| Start date | Feb 1, 2006 |
| First posted | Feb 28, 2006 |
| Last update posted | Oct 10, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: